195.8 billion!

Editor: Chocolate

1.

Medline Industries explores for sale

People familiar with the matter said the family business hired Goldman Sachs to run the process.

It is understood that Medline, headquartered in Northfield, Illinois, may attract private equity bidders, partly because it may be difficult for industry players to swallow such a large competitor.

The Blackstone Group, KKR&Co.

According to the medical device professional website Medical Design, Medline will be a big fish that can be swallowed.

The family-owned Medline provides more than 550,000 medical products and clinical solutions, from surgical gloves to wheelchairs to masks to thermometers.

As the epidemic spreads in 2020, Medline agreed to reprocess thousands of N95 gas masks and other masks in its facilities every day, and began rolling out hand sanitizer at an infection prevention product factory in Wisconsin.

2.

In contrast, in the absence of an epidemic, its revenue increased by 18.

According to the top 100 global medical device companies in 2020 (2020 BIG 100) released by the medical device industry website Medical Design & Outsourcing, Medtronic, Johnson & Johnson, and Philips continue to rank among the top three global medical device companies in terms of revenue, with revenues of 289.

Medline's revenue was $13.

During the epidemic, Medline expanded its coverage to meet the growing demand for masks and other basic medical equipment.

Since 2018, the company's number of employees has remained the same, reporting 27,000 employees.

It is understood that affected by the epidemic, the mask industry has ushered in rapid growth, and many companies have seen a significant increase in their performance.

According to a report issued by the Tehran Chamber of Commerce, the global mask market has reached 140 billion U.
S.
dollars in 2020.

However, according to PR Newswire’s September 2020 data, in 2019, the global market for surgical, facial and respiratory masks was valued at US$2.
1413 billion, and is expected to reach a value of US$15,696.
2 million by 2030.
This market will be valued between 2020 and 2030.
The compound annual growth rate is 5.
7%.

3.
The industry has entered a period of high incidence of mergers and acquisitions?

According to Cyber ​​Blue, the medical device industry seems to be entering a period of high incidence of mergers and acquisitions.

According to Reuters information on April 11, the Italian diagnostic group DiaSorin SpA stated that it will acquire the US-based Luminex company for $1.
8 billion.
This all-cash transaction will strengthen DiaSorin's molecular diagnostic technology.

The transaction is expected to be completed within the third quarter of 2021, generating approximately $55 million in synergies within three years after the completion of the transaction.

DiaSorin SpA, founded in 1968, used to be the in vitro diagnostic department of Sorin Biomedica SpA in Italy.
In 2000, the senior executives of the department subscribed for all stocks and independently established DiaSorin SpA.
It is an independent listed company in Italy.
Its radioimmunoassay and enzyme immunoassay are enjoyed in Europe and the world.
With a high reputation, it has been committed to immunodiagnosis and molecular diagnostic tests in hospitals and private laboratories.

Luminex was founded in 1995 and is headquartered in Austin, Texas, USA.
It was listed on the Nasdaq in the United States in 2000.
It is a company dedicated to the development and production of bioanalytical instruments and their applications in life sciences and clinical diagnosis.
Companies in the field.

In addition, Siemens Medical announced on April 15 that it has successfully completed the acquisition of Varian Medical Systems.
The acquisition transaction was previously disclosed on August 2, 2020.

According to reports, with the completion of the acquisition, Varian is expected to make a positive contribution to Siemens Medical’s earnings per share within the first 12 months.
Siemens Medical’s goal is to achieve at least 300 million euros of synergy each year starting from the 2025 fiscal year.

Prior to this, according to Bloomberg News, Siemens Medical is considering selling its ultrasound business, valued at approximately US$1 billion, equivalent to approximately RMB 6.
5 billion, and many parties are currently negotiating this transaction.

According to people familiar with the matter, the German medical equipment supplier is weighing various options after receiving expressions of interest in the business.
The sale may attract private equity and strategic bidders.

It is understood that at the beginning of November 2020, Siemens Medical announced the 2020 total revenue.
The total revenue in the fiscal year was 14.
46 billion euros, compared with 14.
518 billion euros in the previous fiscal year.
Net profit in the fiscal year was 1.
423 billion euros, compared with 1.
586 billion euros in the previous fiscal year.
Among them, the revenue of imaging and clinical treatment business increased comparatively slightly, while the revenue of diagnostic business declined slightly.